Clinical Trial

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-01-09; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2024-01-24
Trial Details
NCT Number NCT06214143
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Advanced Solid Tumors
Enrollment 68 participants
Start Date 2024-01-11
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05